Dendreon traded up 1.71% on Tuesday, hitting $8.90. Dendreon has a 1-year low of $6.46 and a 1-year high of $43.96. The company’s market cap is $1.371 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at Citigroup (NYSE: C) cut their price target on shares of Dendreon from $14.00 to $10.00 in a research note to investors on Thursday, April 12nd. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Dendreon in a research note to investors on Tuesday, April 3rd. They now have a $11.00 price target on the stock. Finally, analysts at Canaccord Genuity initiated coverage on shares of Dendreon in a research note to investors on Monday, March 26th. They set a “hold” rating and a $11.00 price target on the stock.
Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients.